Legal Accountability: Lawsuits, Verdicts, Manufacturer Conduct, and Barriers Faced by Artificial Stone Workers
March 11, 2026
International Actions and Global Consensus: Australia’s Ban and Worldwide Recognition of the Artificial Stone Crisis
March 9, 2026
The review article “Clinical Importance of Molecular Biomarkers in Pleural Mesothelioma,” published in Cancers in February 2026, examines how advances in molecular biology could improve the treatment of pleural mesothelioma, an aggressive cancer of the lung lining most often caused by asbestos exposure. Written by researchers at The Ohio State University Comprehensive Cancer Center, the article focuses on why current treatments have limited effectiveness and how biological “biomarkers,” measurable features of tumors such as genetic changes or immune signals, may help doctors better predict outcomes and tailor therapies to individual patients.
Pleural mesothelioma remains difficult to treat, with median survival of about one year despite the availability of surgery, chemotherapy, radiation, and newer immunotherapy drugs. One of the key problems, as the authors explain, is that clinicians currently have few reliable ways to determine which patients will benefit from which treatments. The strongest predictor of outcome remains the tumor’s histologic subtype, or how the cancer cells look under a microscope, with some subtypes responding better to chemotherapy and others showing more benefit from immunotherapy. However, this approach alone does not capture the full biological complexity of the disease.
The article reviews several molecular and immune biomarkers that have been studied in mesothelioma, including PD‑L1 expression and tumor mutational burden, which are commonly used in other cancers. In mesothelioma, however, these markers have shown inconsistent results and are not dependable enough to guide routine treatment decisions. This is partly because mesothelioma tumors tend to have relatively few small genetic mutations and instead are driven by larger genetic losses and an immune environment that suppresses effective anti‑tumor responses. As a result, single biomarkers often fail to accurately predict treatment benefit.
One of the most promising developments discussed in the review is the use of circulating tumor DNA (ctDNA), which consists of fragments of tumor genetic material found in the bloodstream. Measuring ctDNA offers a non‑invasive way to monitor molecular response to treatment and detect residual disease or early relapse. Early clinical studies suggest that patients whose ctDNA becomes undetectable after treatment tend to have longer periods without disease progression, highlighting ctDNA’s potential role in guiding treatment decisions and follow‑up care.
The authors also describe several common genetic alterations in mesothelioma, such as loss of MTAP, BAP1, CDKN2A, and NF2 genes, that are increasingly being used within clinical trials to match patients to experimental targeted therapies. While these genetic changes are not yet used to guide standard treatment, they reveal weaknesses in tumor biology that researchers hope to exploit with new drugs. Together, these findings suggest that the future of mesothelioma care will likely depend on combining clinical features, immune markers, and molecular data rather than relying on any single test.
Overall, the article concludes that although biomarker‑driven treatment for pleural mesothelioma is still in its early stages, ongoing research is steadily moving the field toward more personalized care. Continued collaboration, standardized testing methods, and larger biomarker‑focused clinical trials will be essential to translating these scientific advances into meaningful improvements in patient outcomes.
Have You or a Loved One Been Diagnosed with Pleural Mesothelioma?
If you’re living with pleural mesothelioma after asbestos exposure, you should not have to navigate complex medical and legal questions alone. While scientists work to improve treatment through tools like molecular biomarkers and circulating tumor DNA (ctDNA), our attorneys focus on protecting your legal rights and pursuing the compensation you and your family may deserve.
Brayton Purcell LLP has represented mesothelioma victims and their families for decades. We can review your work history, exposure sources, and potential claims at no cost to you.